Probiotics in colon cancer prevention

  • Marlena Wolek Department of Stem Cells and Regenerative Medicine, Institute of Natural Fibres and Medicinal Plants, Poznań, Poland
  • Anna Bogacz Department of Stem Cells and Regenerative Medicine, Institute of Natural Fibres and Medicinal Plants, Poznań, Poland; Department of Histocompatibility with Laboratory of Genetic Diagnostics, Regional Blood Center, Poznań, Poland
  • Bogna Juskowiak Department of Stem Cells and Regenerative Medicine, Institute of Natural Fibres and Medicinal Plants, Poznań, Poland
  • Anna Polaszewska Department of Stem Cells and Regenerative Medicine, Institute of Natural Fibres and Medicinal Plants, Poznań, Poland
  • Bogusław Czerny Department of Pharmacology and Pharmacoeconomics, Pomeranian Medical University, Szczecin, Poland
Keywords: Probiotics, Colon, Cancer, Prevention, Bacteria

Abstract

Probiotics are live, selected microbial strains that have a beneficial effect on the human body and when introduced into the body, they colonize in the digestive tract, especially in the large intestine, exerting a beneficial effect on the health of the host. The microbial strains, so that they can be included in the probiotics, must be thoroughly tested and meet several conditions. These microorganisms multiply in the gastrointestinal tract and are competitive for pathogenic microorganisms that cause infection. Probiotic bacteria are found in natural yogurts, sour milk, sauerkraut, pickled cucumbers. Many studies show a positive correlation between the consumption of probiotics and the risk of developing certain cancers. Probiotics are most likely to reduce the risk of developing colorectal cancer.

DOI: http://dx.doi.org/10.5281/zenodo.1297660

References

1. Tokarz-Deptuła B, Śliwa-Dominiak J, Adamiak M, Deptuła W. Probiotyki a wybrane schorzenia ludzi [in Polish]. Post Mikrobiol. 2015; 54(2): 133-140.

2. Kaźmierska A. Probiotyki - recepta na zdrowie? Kosmos. 2014; 63(3): 455-472.

3. Jach M, Łoś R, Maj M, Malm A. Probiotyki - aspekty funkcjonalne i technologiczne [in Polish]. Post Mikrobiol. 2013; 52(2): 161-170.

4. Lutyńska A, Augustynowicz E, Wiatrzyk A. Problemy stosowania suplementów diety zawierających probiotyki [in Polish]. Probl Hig Epidemiolog. 2012; 93(3): 493-498.

5. Saarela M, Mogensen G, Fonden R, Matto J, Mattila-Sandholm T. Probiotic bacteria: safety, functional and technological properties. J Biotechnol. 2000; 84(3): 197-215.

6. Krajewska-Kamińska E, Śmietana Z, Bohdziewicz K. Bakterie probiotyczne w produkcji żywności [in Polish]. Przem Spoż. 2007; 61(5): 36-41.

7. Jakubczyk E, Kosikowska M. Nowa generacja mlecznych produktów fermentowanych z udziałem probiotyków i prebiotyków, produkty synbiotyczne [in Polish]. Przem Mlecz. 2000; 12: 397-400.

8. Strus M, Heczko P, Kochan P. Projektowanie probiotyków do zastosowań medycznych [in Polish]. Post Mikrobiol. 2008; 47(3): 11-66.

9. De Vuyst L. Hamujące działanie probiotycznych bakterii kwasu mlekowego. Probiotyki [in Polish]. Warsztaty zorganizowane w ramach projektu Accompanying Measure do projektu Flair-Flow Europe IV. 2002: 23-27.

10. Prost E. Probiotyki [in Polish]. Med Wet. 1999; 2: 75-79.

11. Gajewska D. Probiotyki [in Polish]. Prz Gastr. 2003; 8: 14-15.

12. Zduńczyk Z. Probiotyki i synbiotyki oddziaływania lokalne i systemowe [in Polish]. Przem Spoż. 2002; 4: 6-8.

13. Libudzisz Z. Probiotyki i prebiotyki w fermentowanych napojach mlecznych [in Polish]. Pediatr Współcz Gastroenterol Hepatol Żyw Dziecka. 2002; 4(1): 19-25.

14. Siuta A. Biomechaniczna aktywność probiotyków w organizmie [in Polish]. Med Wet. 1994; 12: 593-596.

15. Wollowski I, Rechkemmer G, Pool-Zobel BL. Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr. 2001; 73(2): 451-455.

16. Rafter J. Probiotics and colon cancer. Best Pract Res Clin Gastroenterol. 2003; 17(5): 849-859.

17. Min-Tze L. Roles of probiotics and prebiotics in colon cancer prevention: postulated mechanisms and in-vivo evidence. Int J Mol Sci. 2008; 9(5): 854-863.

18. Heczko P, Strus M, Jawień M, et al. Medyczne zastosowanie probiotyków [in Polish]. Wiad Lek. 2005; 11-12: 640-646.

19. Yang S-CH, Lin Ch-H, Sung C, et al. Antibacterial activities of bacteriocins: application in foods and pharmaceuticals. Front Microbiol. 2014; 5: 241.

20. Kaur S, Kaur S. Bacteriocins as potential anticancer agents. Front Pharmacol. 2015; 6: 272.

21. Kubiak A, Kycler W, Trojanowski M. Epidemiologia i profilaktyka raka jelita grubego w Polsce [in Polish]. Probl Hig Epidemiol. 2014; 95(3): 636-642.

22. Marlicz W, Łoniewski I. Mikroflora jelitowa a otyłość i rak jelita grubego [in Polish]. Gastroenterol Klin. 2012; 4(2): 69-78.

23. Reddy BS, Hamid R, Rao CV. Effect of dietary oligofructose and inulin on colonic preneoplastic aberrant crypt foci inhibition. Carcinogenesis. 1997; 18: 1371-1374.

24. Kulkarni N, Reddy BS. Inhibitory effect of Bifidobacterium longum cultures on the azoxymethane-induced aberrant crypt foci formation and fecal bacterial β-glucuronidase. Proc Soc Exp Biol Med. 1994; 207: 278-283.

25. Guengerich, FP. Cytochromes P450, drugs, and diseases. Mol Interv. 2003; 3: 194-204.

26. Campbell TC, Hayes JR. The effect of quantity and quality of dietary protein on drug metabolism. Feder Proc. 1976; 35: 2470-2474.

27. Usman, Hosono A. Desmutagenicity of milk cultured with Lactobacillus acidophilus strains against mutagenic heated tauco. Food Chem Toxicol. 1998; 36: 805-810.

28. Thyagaraja N, Hosono A. Antimutagenicity of lactic acid bacteria from “Idly” against food-related mutagens. J Food Protect. 1993; 56: 1061-1066.

29. Sekine K, Ohta J, Onishi M, Tatsuki T, Shimokawa Y, Toida T, et al. Analysis of antitumor properties of effector cells stimulated with a cell wall preparation (WPG) of Bifidobacterium infantis. Biol Pharmac Bull. 1995; 18: 148-153.

30. Okawa T, Niibe H, Arai T, Sekiba K, Noda K, Takeuchi S, et al. Effect of LC9018 combined with radiation therapy on carcinoma of the uterine cervix. Cancer. 1993; 72: 1949-1954.

31. Zhang XB, Ohta Y. Binding of mutagens by fractions of the cell wall skeleton of lactic acid bacteria on mutagens. J Dairy Sci. 1991; 74: 1477-1481.

32. Drasar BS, Hill MJ. Human intestinal flora. New York, Academic Press Inc. 1974.

33. Lang NP, Butler MA, Massengill J, Lawson M, Stotts RC, Maurer-Jensen M, et al. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev. 1994; 3: 675-682.

34. Singh J, Rivenson A, Tomita M, Shimamura S, Ishibashi N, Reddy BS. Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis. Carcinogenesis. 1997; 18: 833-841.

35. Zhang XB, Ohta Y. Microorganisms in the gastrointestinal tract of the rat prevent absorption of the mutagen-carcinogen 3-amino- 1,4-dimethyl-5H-pyrido[4,3-b]indole. Can J Microbiol. 1993; 39: 841-845.

36. Thyagaraja N, Hosono A. Antimutagenicity of lactic acid bacteria from “Idly” against food-related mutagens. J Food Protect. 1993; 56: 1061-1066.

37. Surono IS, Hosono A. Antimutagenicity of milk cultured with lactic acid bacteria from Dadih against mutagenic Terasi. Milchwissenschaft. 1996; 51: 493-497.

38. Baricault L, Denariaz G, Houri JJ, Bouley C, Sapin C, Trugnan G. Use of HT-29, a cultured human colon cancer cell line, to study the effect of fermented milks on colon cancer cell growth and differentiation. Carcinogenesis. 1995; 16: 245-252.

39. Moorehead RJ, Hoper M, McKelvey STD. Assessment of ornithine decarboxylase in rectal mucosa as a marker for colorectal adenomas and carcinomas. Brit J Surg. 1987; 74: 364-365.

40. Fearon ER, Vogelstein B. A Genetic model for colorectal tumorigenesis. Cell. 1990; 61: 759-767.

41. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature. 1987; 327: 298-303.

42. Nowak A, Śleżewska K, Libudzisz Z, Socha J. Probiotyki - efekty zdrowotne [in Polish]. Żywność Nauka Technologia Jakość. 2010; 4: 20-36.

43. Mossop H, Linhares IM, Bongiovanni AM, Ledger WJ, Witkin SS. Influence of lactic acid on endogenous and viral RNA-induced immune mediator production by vaginal epithelial cells. Obstet Gynecol. 2013; 118: 840-846.

44. Hirayama K, Rafter J. The role of probiotic bacteria in cancer prevention. Microbes Infection. 2000; 2(6): 681-686.
Published
2018-06-25
How to Cite
Wolek, M., Bogacz, A., Juskowiak, B., Polaszewska, A., & Czerny, B. (2018). Probiotics in colon cancer prevention. MicroMedicine, 6(2), 62-68. Retrieved from http://journals.tmkarpinski.com/index.php/mmed/article/view/50
Section
Review Articles